{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:49:03Z","timestamp":1792097343164,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000046","name":"National Research Council Canada","doi-asserted-by":"publisher","award":["CGT-501-2"],"award-info":[{"award-number":["CGT-501-2"]}],"id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2RS-2024-00509114"],"award-info":[{"award-number":["2RS-2024-00509114"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["1057810"],"award-info":[{"award-number":["1057810"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-195765"],"award-info":[{"award-number":["PJT-195765"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.canlet.2025.218235","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:01:10Z","timestamp":1766592070000},"page":"218235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary disease"],"prefix":"10.1016","volume":"639","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-3287","authenticated-orcid":false,"given":"Shelby","family":"Kaczmarek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyeon","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Ghaziasgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-6100","authenticated-orcid":false,"given":"Stefania","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Arbabi Ghahroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihue","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-7864","authenticated-orcid":false,"given":"Scott","family":"McComb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-6421","authenticated-orcid":false,"given":"Seung-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218235_bib1","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218235_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.canlet.2025.218235_bib3","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma: ASH 50th anniversary review","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib5","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38- targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.218235_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2025.218235_bib7","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218235_bib8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218235_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.218235_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/hematology.2023000518","article-title":"Barriers to accessing cellular therapy for patients receiving care in community practices","volume":"2023","author":"Nze","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.canlet.2025.218235_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-Cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm. Med."},{"key":"10.1016\/j.canlet.2025.218235_bib12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218235_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218235_bib15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.mgene.2014.09.008","article-title":"KIR genotype distribution among patients with multiple myeloma: higher prevalence of KIR 2DS4 and KIR 2DS5 genes","volume":"2","author":"Hoteit","year":"2014","journal-title":"Meta Gene."},{"key":"10.1016\/j.canlet.2025.218235_bib17","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1182\/blood-2012-06-438028","article-title":"A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Benson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2002.03879.x","article-title":"Anti-myeloma activity of natural killer lymphocytes","volume":"119","author":"Frohn","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2025.218235_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0065-2776(04)86006-1","article-title":"Interleukin-2, interleukin-15, and their roles in human natural killer cells","volume":"86","author":"Becknell","year":"2005","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.canlet.2025.218235_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/imr.13255","article-title":"Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer","volume":"320","author":"Li","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2025.218235_bib21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.canlet.2025.218235_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218235_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2025.218235_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.omtm.2023.03.006","article-title":"Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles","volume":"29","author":"Jo","year":"2023","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.canlet.2025.218235_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained Ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218235_bib26","first-page":"1","article-title":"Expansion, purification, and functional assessment of human peripheral blood NK cells","author":"Somanchi","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.canlet.2025.218235_bib27","series-title":"Anti-Bcma Single Domain Antibodies and Therapeutic Constructs","author":"Arbabi-Ghahroudi","year":"2023"},{"key":"10.1016\/j.canlet.2025.218235_bib28","article-title":"Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22","volume":"32","author":"McComb","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.canlet.2025.218235_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-Cell transduction with baboon envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218235_bib30","first-page":"1","article-title":"A distinct subset of highly proliferative and lentiviral vector (LV)-Transducible NK cells define a readily engineered subset for adoptive cellular therapy","volume":"10","author":"Bari","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218235_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.864868","article-title":"Programmable attenuation of antigenic sensitivity for a nanobody-based EGFR chimeric antigen receptor through Hinge domain truncation","volume":"13","author":"McComb","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218235_bib32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2025.218235_bib33","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1002\/ajh.25399","article-title":"Allogeneic CAR T cell therapies for leukemia","volume":"94","author":"Qasim","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.218235_bib34","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.218235_bib36","first-page":"1","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2025.218235_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218235_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-023-00461-8","article-title":"Single VHH-Directed BCMA CAR-NK cells for multiple myeloma","volume":"12","author":"Ren","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218235_bib39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2025.218235_bib40","article-title":"Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15","volume":"13","author":"Tian","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218235_bib41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","article-title":"Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable Antitumor efficacy","volume":"53","author":"Li","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2025.218235_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1533044","article-title":"Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression","volume":"16","author":"Jo","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218235_bib43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bjh.13384","article-title":"Extramedullary disease in multiple myeloma in the era of novel agents","volume":"169","author":"Blad\u00e9","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2025.218235_bib44","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3109\/10428194.2015.1128542","article-title":"Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients","volume":"57","author":"Jurczyszyn","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2025.218235_bib45","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s00432-024-05993-y","article-title":"Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma","volume":"150","author":"Zolnowski","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218235_bib46","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218235_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs","volume":"105","author":"Montefusco","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.218235_bib48","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.7863\/ultra.32.10.1777","article-title":"Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma : Comparison with serologic data","volume":"32","author":"Pintoffl","year":"2013","journal-title":"J. Ultrasound Med."},{"key":"10.1016\/j.canlet.2025.218235_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008769","article-title":"Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma","volume":"12","author":"Korst","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218235_bib50","article-title":"V\u03b39V\u03b42 T cells expressing a BCMA\u2014Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth","volume":"17","author":"Zhang","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218235_bib51","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1182\/bloodadvances.2023010410","article-title":"Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma","volume":"7","author":"Wachsmann","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.canlet.2025.218235_bib52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.canlet.2025.218235_bib53","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","article-title":"Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model","volume":"18","author":"Thangaraj","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2025.218235_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080889","article-title":"Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models","volume":"8","author":"Okada","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2025.218235_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071915","article-title":"Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies","volume":"12","author":"Mhaidly","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.218235_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1847.1847","article-title":"The humanized multiple myeloma mouse model: opportunities for studying the pathogenesis of MM in its natural environment","volume":"114","author":"Groen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib57","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219439120","article-title":"Mouse models of human multiple myeloma subgroups","volume":"120","author":"Winkler","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218235_bib58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218235_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009476","article-title":"BCMA-BBZ-OX40 CAR-T therapy using an instant manufacturing platform in multiple myeloma","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218235_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177300","article-title":"Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice","volume":"9","author":"Hasanali","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2025.218235_bib61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00432-021-03854-6","article-title":"Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma","volume":"148","author":"Waldschmidt","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218235_bib62","article-title":"Ex vivo maintenance of primary human multiple myeloma cells through the optimization of the osteoblastic niche","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218235_bib63","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2022-170119","article-title":"Extramedullary relapse post CAR-T","volume":"140","author":"Richard","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib64","article-title":"Outcomes after CAR T cells in multiple myeloma patients with extramedullary and paramedullary disease","volume":"142","author":"Pan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib65","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/ajh.27469","article-title":"Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy","volume":"99","author":"Qi","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.218235_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-Cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2025.218235_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010687","article-title":"Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Jin","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218235_bib68","article-title":"BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial","volume":"18","author":"Yao","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218235_bib69","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Kararoudi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218235_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000320","article-title":"BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2025.218235_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70046","article-title":"Natural killer cell engagers: from bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy","volume":"14","author":"Zhu","year":"2024","journal-title":"Clin. Transl. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525008079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525008079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:38:03Z","timestamp":1792096683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525008079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":71,"alternative-id":["S0304383525008079"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218235","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary disease","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218235"}}